Clolar — Competitive Intelligence Brief

Clolar (CLOFARABINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside Metabolic Inhibitor [EPC]. Area: Oncology.

marketed Nucleoside Metabolic Inhibitor [EPC] Ribonucleoside-diphosphate reductase large subunit Oncology Small molecule

Target snapshot

Clolar (CLOFARABINE) — Sanofi. Clolar works by inhibiting the enzyme responsible for DNA synthesis, thereby preventing cancer cells from reproducing.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Clolar TARGET	CLOFARABINE	Sanofi	marketed	Nucleoside Metabolic Inhibitor [EPC]	Ribonucleoside-diphosphate reductase large subunit	2004-01-01
Fludarabin	Fludarabin	Azienda Ospedaliera San Giovanni Battista	marketed		Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit
Fludara	Fludara	Celyad Oncology SA	marketed		Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit
Gemcitabin	Gemcitabin	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	marketed		UMP-CMP kinase, Deoxycytidine kinase, Ribonucleoside-diphosphate reductase large subunit
Inqovi	Inqovi	Otsuka	marketed	Nucleoside Metabolic Inhibitor [EPC]	Cytidine deaminase	2020-01-01
CEDAZURIDINE	CEDAZURIDINE		marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA methyltransferase	2020-01-01
Dacogen	decitabine	Sun Pharma	marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA (cytosine-5)-methyltransferase 1	2006-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2028-10-16 — Inqovi · 8618075 · US
• 2028-10-16 — Inqovi · 9567363 · US
• 2030-08-22 — Inqovi · 8268800 · US

Sponsor landscape (Nucleoside Metabolic Inhibitor [EPC] class)

1. · 4 drugs in this class
2. Bristol-Myers Squibb · 1 drug in this class
3. Cheplapharm · 1 drug in this class
4. Extrovis · 1 drug in this class
5. Hospira Inc · 1 drug in this class
6. Novartis · 1 drug in this class
7. Otsuka · 1 drug in this class
8. Pfizer Inc. · 1 drug in this class
9. Sanofi · 1 drug in this class
10. Sun Pharma · 1 drug in this class